Global antibiotic resistance, driven by intensive antibiotic exposure/abuse, constitutes a serious challenge to all health care, particularly in an era when new antimicrobial development has slowed to a trickle. Recently, we published work demonstrating the discovery and partial mechanism of action of a novel bactericidal agent that is effective against both gram-positive and gram-negative multidrug-resistant bacteria. This drug, called AB569, consists of acidified nitrite (A-NO2−) and EDTA, of which there is no mechanism of resistance. Using both chemistry-, genetic-, and bioinformatics-based techniques, we first discovered that AB569 was able to generate bactericidal levels of nitric oxide (NO), while the EDTA component stabilized S-nitrosyl thiols, thereby furthering NO and downstream reactive nitrogen species production. This elegant chemistry triggered a paralytic downregulation of vital genes using RNA-seq involved in the synthesis of DNA, RNA, ATP, and protein in the representative ESKAPE pathogen, Pseudomonas aeruginosa.
Get full access to this article
View all access options for this article.
References
1.
AlakomiH.L., PaananenA., SuihkoM.L., HelanderI.M., and SaarelaM. (2006). Weakening effect of cell permeabilizers on gram-negative bacteria causing biodeterioration. Appl Environ Microbiol, 72, 4695–4703.
2.
DaviesD.G., ParsekM.R., PearsonJ.P., IglewskiB.H., CostertonJ.W., and GreenbergE.P. (1998). The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science, 280, 295–298.
3.
HassettD.J. (1996). Anaerobic production of alginate by Pseudomonas aeruginosa: alginate restricts diffusion of oxygen. J Bacteriol, 178, 7322–7325.
4.
HassettD.J., SuttonM.D., SchurrM.J., HerrA.B., CaldwellC.C., and MatuJ.O. (2009). Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol, 17, 130–138.
KhanU., MehtaR., ArifM.A., and LakhaniO.J. (2020). Pandemics of the past: a narrative review. J Pak Med Assoc, 70(Suppl 3), S34–S37.
7.
KolpenM., KuhlM., BjarnsholtT., MoserC., HansenC.R., LiengaardL., et al. (2014). Nitrous oxide production in sputum from cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. PLoS One 9,e84353.
8.
MartinD.W., SchurrM.J., MuddM.H., GovanJ.R., HollowayB.W., and DereticV. (1993). Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci U S A, 90, 8377–8381.
9.
MatsuiH., WagnerV.E., HillD.B., SchwabU.E., RogersT.D., ButtonB., et al. (2006). A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A, 103, 18131–18136.
10.
MatsushitaK., AdachiO., ShinagawaE., and AmeyamaM. (1978). Isolation and characterization of outer and inner membranes from Pseudomonas aeruginosa and effect of EDTA on the membranes. J Biochem, 83, 171–181.
11.
McDanielC., SuS., PanmaneeW., LauG.W., BrowneT., CoxK., et al. (2016). A putative ABC transporter permease is necessary for resistance to acidified nitrite and EDTA in Pseudomonas aeruginosa under aerobic and anaerobic planktonic and biofilm conditions. Front Microbiol 7,291.
12.
McDanielC.T., PanmaneeW., WinsorG.L., GillE., BertelliC., SchurrM.J., et al. (2020). AB569, a nontoxic chemical tandem that kills major human pathogenic bacteria. Proc Natl Acad Sci U S A, 117, 4921–4930.
13.
PoglianoJ., PoglianoN., and SilvermanJ.A. (2012). Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol, 194, 4494–4504.
14.
ShaeerK.M., ZmarlickaM.T., ChahineE.B., PiccicaccoN., and ChoJ.C. (2019). Plazomicin: a next-generation aminoglycoside. Pharmacotherapy, 39, 77–93.
15.
SharmaD., MisbaL., and KhanA.U. (2019). Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrob Resist Infect Control 8,76.
16.
SloverC.M., RodvoldK.A., and DanzigerL.H. (2007). Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother, 41, 965–972.
17.
SrivastavaA., TalaueM., LiuS., DegenD., EbrightR.Y., SinevaE., et al. (2011). New target for inhibition of bacterial RNA polymerase: ‘switch region’. Curr Opin Microbiol, 14, 532–543.
18.
SuS., and HassettD.J. (2012). Anaerobic Pseudomonas aeruginosa and other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or “Old Hat”?. Expert Opin Ther Targets, 16, 859–873.
19.
SwaneyS.M., AokiH., GanozaM.C., and ShinabargerD.L. (1998). The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother, 42, 3251–3255.
20.
TanS.Y., and GrimesS. (2010). Paul Ehrlich (1854–1915): man with the magic bullet. Singapore Med J, 51, 842–843.
21.
WorlitzschD., TarranR., UlrichM., SchwabU., CekiciA., MeyerK.C., et al. (2002). Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa cystic fibrosis airway infection. J Clin Invest, 109, 317–325.
22.
YoonS.S., CoakleyR., LauG.W., LymarS.V., GastonB., KarabulutA.C., et al. (2006a). Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest, 116, 436–446.
23.
YoonS.S., CoakleyR., LauG.W., LymarS.V., GastonB., KarabulutA.C., et al. (2006b). Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest, 116, 436–446.
24.
YoonS.S., HenniganR.F., HilliardG.M., OchsnerU.A., ParvatiyarK., KamaniM.C., et al. (2002). Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell. 3, 593–603.
25.
YoonS.S., KarabulutA.C., LipscombJ.D., HenniganR.F., LymarS.V., GroceS.L., et al. (2007). Two-pronged survival strategy for the major cystic fibrosis pathogen, Pseudomonas aeruginosa, lacking the capacity to degrade nitric oxide during anaerobic respiration. EMBO J, 26, 3662–3672.
